ClinicalTrials.gg
RecruitingNCT06732180Updated May 6, 2025

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

A Phase 1 interventional study of GT-02287 in Parkinson Disease, sponsored by Gain Therapeutics, Inc.. Recruiting at 7 sites in Australia. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by Gain Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Parkinson Disease with a site in Australia — 10 open to participants now, 12 under way, 3 of them phase 3. Parkinson Disease · Australia.

Planned enrollment
50th of 54
20 · median 132
Started
2025
with 3 others
Phase 1
8 of 59
4 open now
Primary completion
2025-11
later than 1 of 11 live
Registered
53rd of 59
by date

Among the 59 studies in Parkinson Disease with a site in Australia, this one is the 50th largest by planned enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2025, is one of 8 in phase 1, reaches primary completion later than 1 of the 11 other live ones, and was the 53rd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

10 of the 59 studies in Parkinson Disease with a site in Australia are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Parkinson Disease with a site in Australia, or all of them as a file.
02

Study summary

The main goal of this clinical trial is to learn about the safety and tolerability of GT-02287. The questions it aims to answer are:

  • What medical problems do participants have when taking GT-02287?
  • How is GT-02287 absorbed, distributed, and removed from the body of participants over time (pharmacokinetics)?
  • Are there any biological effects of GT-02287 in blood and in cerebrospinal fluid that could be beneficial for people with Parkinson's disease?

Participants will:

  • visit the clinic to assess if they qualify for the study (30-day Screening Period)
  • if eligible, receive GT-02287 once a day every day for 90 days (90-day Open Label Treatment period)
  • visit the clinic the first day of treatment, after the first 2 weeks of treatment, and every month during the 90-day Treatment Period.
  • visit the clinic to assess how they are doing 14 days after the end of GT-02287 treatment (14-day Follow-Up Period).
Read the detailed description

This Phase 1b, 3-month, multicenter, open-label study of GT-02287 in participants with Parkinson's Disease with or without GBA1 mutations. The primary objective of the study is to evaluate the safety and tolerability of GT-02287. The study will also investigate pharmacokinetics (PK) and explore pharmacodynamic parameters in blood and CSF and effect of GT-02287 on scores from selected clinical scales. Approximately 20 participants will be enrolled to result in approximately 15 evaluable participants.

All participants will receive an oral dose of GT-02287 of 13.5 mg/kg/day (plus/minus 2 mg/kg/day) once a day for 90 days.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to provide written and be willing to comply with the requirements and restrictions of the study
  • Any sex, ≥30 and ≤85 years of age
  • Diagnosis of PD based on MDS criteria
  • Within 7 years of PD diagnosis
  • of ≥18 and ≤40 kg/m2, and a body weight ≥45 kg and ≤120 kg
  • Willing to provide a blood sample for PD-related genetic testing
  • Hoehn \& Yahr 1-3, inclusive
  • No severe motor fluctuations or disabling dyskinesias based on the investigator's clinical assessment
  • Naïve to pharmacological treatment for PD or on stable PD medication for ≥3 months prior to Screening, including ≥4 weeks at the same dose(s) immediately before Screening
  • Not pregnant or breastfeeding
  • If participant is either of or produces potentially viable sperm, participant must agree to use 2 forms of (barrier method and a second highly effective form of birth control/contraception, as defined in the protocol) if engaging in potentially reproductive intercourse (with a partner who produces potentially viable sperm or is of childbearing potential, respectively)
  • Agreeing to not participate in another study while taking part in this study
  • For participants with known GBA1 mutations, presence of a GBA1 mutation that has been associated with an increased risk of PD

Exclusion criteria

Exclusion Criteria:

  • Other neurological disorders, including but not limited to Alzheimer's disease, amyotrophic lateral sclerosis, frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome, Huntington's disease, multiple system atrophy, dementia with Lewy bodies, secondary (e.g. drug-induced) parkinsonism, multiple sclerosis, or epilepsy
  • A history of Gaucher disease or homozygous for a GBA1 pathogenic variant known to be associated with GD or compound heterozygous for 2 alleles that are known to be associated with GD.
  • Known PD-associated LRRK2 pathogenic variant or other PD-associated genetic mutations other than GBA1
  • Dementia or a moderate cognitive impairment (score ≥17 on the )
  • to GT-02287 or any of its
  • Concomitant medications metabolized primarily by cytochrome P450 3A4 () that have a narrow therapeutic window, concomitant medications that are substrates of breast cancer resistance protein and/or P-glycoprotein and that have a narrow therapeutic window, concomitant medications that are potent inhibitors or inducers of CYP3A4
  • Use of dopamine antagonists (antipsychotics) or anticholinergic medications
  • Concomitant disease including, but not limited to cardiovascular conditions, diabetes, disease, cancer, active infectious disease, psychotic disorders and symptoms, depressive symptoms, drug and/or alcohol misuse as defined in the protocol
  • Malabsorption or relevant disorder which may impact the absorption of GT-02287
  • abnormalities in laboratory test
  • to lumbar puncture (LP)
  • Blood donation >500 mL within 3 months
  • Unable to comply with restrictions on food products, smoking, and /or alcohol use as defined in protocol
  • participation in any interventional clinical study within 3 months or 5 half-lives, whichever is longer, prior to Screening
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    single-arm. All participants receive the active molecule (once daily GT-02287 administration)

    Drug: GT-02287

Interventions

  • DrugGT-02287

    Dose of 13.5 mg/kg/day (plus/minus 2 mg/kg/day based on body weight) to be administered orally once a day for 90 days. Dosage form: powder in sachet (200 mg of GT-02287 per sachet) for reconstitution with a suspending agent

06

What researchers measure

Primary outcomes

  1. Incidence, nature, relationship to investigational product (IP), and severity of adverse events (AEs)

    Time frame: From first dose to Day 105

  2. Incidence of clinically significant findings for clinical laboratory evaluations, physical and neurological examinations, body weight , vital signs measurements, 12-lead o 12-lead electrocardiograms (ECGs), Columbia Suicide Severity Rating Scale (C-SSRS)

    Time frame: From first dose to Day 105

Secondary outcomes

  1. Maximum Plasma Concentration [Cmax]

    Pharmacokinetics

    Time frame: Day 1 and Day 90

  2. Area under the curve [AUC]

    Pharmacokinetics

    Time frame: Day 1 and Day 90

  3. Time to reach Cmax [Tmax]

    Pharmacokinetics

    Time frame: Day 1 and Day 90

  4. Elimination half life [T1/2]

    Pharmacokinetics

    Time frame: Day 90- Day 93

  5. Apparent Clearance (CL/F)

    Pharmacokinetics

    Time frame: Day 90- Day 93

  6. Apparent Volume of Distribution (Vz/F)

    Pharmacokinetics

    Time frame: Day1 and Day 90- Day 93

Other outcomes

  1. Gcase activity (µmol/L/h) measurement in dried blood spots (DBS)

    Pharmacodynamics (Exploratory outcome): mean change from baseline in Gcase activity in DBS

    Time frame: From first dose to Day 90

  2. Concentration of sphingolipids in cerebrospinal fluid (CSF )

    Pharmacodynamics (Exploratory outcome): mean change from baseline in sphingolipids in CSF

    Time frame: From first dose to Day 90

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Nov 2025, 9 months after the start.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 9 months is close to that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 13, 2024
StartActual
Feb 21, 2025
Primary completionEst.
Nov 30, 2025
CompletionEst.
Nov 30, 2025
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06732180
Lead sponsor
Gain Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Feb 21, 2025
Primary completion
Nov 30, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
May 6, 2025

Study contacts

Gain Therapeutics Clinical Operations
Contact
info@gaintherapeutics.com
+41919211131
Chief Medical Officer
study director · Gain Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion